In light of the finding that the application of BH3-mimetics induces compensatory A1 overexpression in human CLL and NHL-model cell lines, further studies into the role of A1/BFL-1 as a survival and drug-resistance factor in human blood cancer are warranted. This evidence concerns the gene BCL2A1 and non-Hodgkin lymphoma.